Shares of Rockwell Medical RMTI fell 2.17% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share rose 16.67% over the past year to ($0.10), which were in line with the estimate of ($0.10).
Revenue of $15,280,000 declined by 0.82% year over year, which missed the estimate of $15,670,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Rockwell Medical hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Nov 09, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/u4c5is7w
Price Action
Company's 52-week high was at $3.85
Company's 52-week low was at $0.83
Price action over last quarter: down 48.85%
Company Description
Rockwell Medical Inc is a US-based fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease with its products and services for the treatment of iron deficiency, and hemodialysis. The company's drug products are Triferic and Calcitriol. Triferic is a therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Calcitriol is a generic drug for treating secondary hyperparathyroidism in dialysis patients. The company operates in one segment of the hemodialysis market which involves the manufacture, sale, and distribution of hemodialysis products. The majority of the revenue is generated form the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
